A Study of Nasal Glucagon in Participants With a Common Cold

Exclusion Criteria

• •Presence of any nose piercings.
• •History of significant hypersensitivity to glucagon, oxymetazoline or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs.
• •Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects.
• •Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease.
• •Presence of severe fever (more than 39.5 degrees Celsius) at screening or prior to dosing of period 1.
• •Presence of clinically significant findings on nasal examination or bilateral anterior rhinoscopy, such as structural abnormalities, nasal polyps, marked septal deviation, nasal tumors.
• •Presence or history of Type 1 or Type 2 diabetes.
• •Presence or history of significant hypoglycemia or hyperglycemia.
• •Use of beta-blockers, indomethacin, warfarin or anticholinergic drugs in the previous 28 days before day 1 of the study.
• •Fasting blood glucose above 6.1 mmol/L at screening, following a 12-hour fasting period.
• •Fasting blood glucose assessed with a glucose meter above 6.1 mmol/L approximately 0.5 hour before each dosing.